Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity titled "Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)" aimed at accelerating the development of device-based treatments for Substance Use Disorders (SUDs). This initiative seeks to support both pre-clinical and clinical development phases through a cooperative agreement format, which includes an initial UG3 phase of up to two years, followed by a potential UH3 phase lasting three additional years, contingent upon successful milestone achievement. The program emphasizes innovative approaches to understanding device mechanisms and treatment outcomes, particularly for SUDs lacking effective current treatments, and requires proposals to include quantifiable milestones and collaboration with NIH staff. Interested applicants can find more information and submission guidelines at the provided link, with an award ceiling of $500,000 and a closing date for applications set for August 13, 2026. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.